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To evaluate whether the epidermal growth factor receptor (EGFR), K-Ras and PTEN, all members of the EGFR signalling pathway,
may affect the clinical response in cetuximab-treated metastatic colorectal cancer (mCRC) patients. Twenty-seven cetuximab-treated
mCRC patients were evaluated for drug response and investigated for EGFR protein expression and gene status, K-Ras mutational
status and PTEN protein expression. Ten patients achieved a partial response (PR) to cetuximab-based therapy. All 27 patients
showed EGFR protein overexpression. Epidermal growth factor receptor gene amplification was observed in eight out of 27 (30%)
and chromosome 7 marked polysomy in 16 (59%) patients. Partial response was observed in six out of eight patients with EGFR gene
amplification, four out of 16 with marked polysomy and none out of three with eusomy (Po0.05). The K-Ras wild-type sequence was
observed in 17 patients, and nine of them experienced a PR. Conversely, K-Ras was mutated in 10 cases, of which one patient
experienced a PR (Po0.05). The PTEN protein was normally expressed in 16 patients, and 10 of them achieved a PR. In contrast, no
benefit was documented in 11 patients with loss of PTEN activity (Po0.001). Patients with EGFR gene amplification or chromosome
7 marked polysomy respond to cetuximab. In addition to K-Ras mutations, we demonstrate for the first time that the loss of PTEN
protein expression is associated with nonresponsiveness to cetuximab.
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Metastatic colorectal cancer (mCRC) is a leading cause of cancer
death worldwide, and despite recent advances in chemotherapeutic
treatment, there is a continuous need for more effective therapies.
More recently, specific molecular processes have been targeted for
therapeutic interventions. The epidermal growth factor receptor
(EGFR) is one of four HER-family tyrosine kinases (EGFR, erbB2,
erbB3, erbB4) that initiates intracellular proliferation signalling.
The activation results in proliferation and survival through the
Ras/Raf/MEK/ERK or PI3K/PTEN/AKT pathways, respectively
(Baselga, 2001). The activated EGFR also regulates the production
of angiogenic factors and permits tumour invasion through
extracellular matrix components. In mCRC, the expression of
EGFR, which can be demonstrated in approximately 70% of cases,
correlates with poor prognosis (Mayer et al, 1993). Given the
myriad of downstream effects, its frequency of overexpression, and
its correlation with prognosis, various approaches have been
considered to inhibit EGFR, including monoclonal antibodies
(MoAb) and small molecule inhibitors. In mCRC, the clinical
development focused on cetuximab, a chimaeric mouse/human
MoAb of the IgG1 subclass, that binds to the extracellular region of
the receptor and functions as a competitive antagonist that inhibits
ligand binding, leading to the blockage of EGFR downstream
pathway.
Several clinical trials including cetuximab have been conducted
in mCRC, not only in patients refractory to irinotecan-based
chemotherapy, but also as single agent or as first- or second line in
combination with oxaliplatin-based regimens. All these studies
indicated that only a subgroup of patients treated with cetuximab
may benefit from the drug (Rosenberg et al, 2002; Van Laethem
et al, 2003; Cunningham et al, 2004; Saltz et al, 2001, 2004;
Tabernero et al, 2004; Jennis et al, 2005; Borner et al, 2006;
Folprecht et al, 2006; Venook et al, 2006; Wilke et al, 2006). Based
on preclinical findings, it should be outlined that the trials
including cetuximab have been performed in patients who
expressed EGFR protein in primary tumours based on immuno-
histochemistry (IHC). However, no correlation has been shown
between efficacy of cetuximab and intensity of EGFR staining in
tumours (Cunningham et al, 2004; Saltz et al, 2004). In addition,
response to cetuximab has been observed also in patients with
EGFR-negative tumours (Chung et al, 2005). These data indicate
that EGFR expression by IHC is insufficient to determine
candidacy for cetuximab therapy. No reliable markers have so
far been characterised to identify patients who will benefit from
cetuximab therapy, and only skin reaction has been significantly
associated with response and overall survival (OS) (Cunningham
et al, 2004; Saltz et al, 2004). However, recent data suggest that the
EGFR gene status may predict response to cetuximab (Moroni
et al, 2005), while K-Ras point mutations seem to confer resistance
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sto this drug (Lievre et al, 2005; Di Fiore et al, 2007). Our study
aimed to examine whether molecular determinants such as the
EGFR gene status and the EGFR downstream cascade members K-
Ras and PTEN, which are altered in a significant proportion of
sporadic CRC independently of the EGFR status, may serve as
markers in predicting response in patients with mCRC treated with
cetuximab.
PATIENTS AND METHODS
Patient population and treatment regimens
We analysed 27 consecutive patients, who gave informed consent,
with histologically confirmed mCRC at the Institute of Pathology,
Locarno, Switzerland. All patients were treated with cetuximab-
based regimens at the Oncology Institute of Southern Switzerland,
18 of them treated within clinical trials. All patients had EGFR
expression in their primary tumour specimens at IHC.
With the exception of four patients who received cetuximab as
frontline therapy, the others had failed at least one prior
chemotherapy regimen (Table 1). For those who progressed on
irinotecan-based chemotherapy, the MoAb was administered in
combination with irinotecan given at the same dose and schedule
previously used. Cetuximab was administered at standard loading
dose of 400mgm
 2 over 2h, followed by weekly 250mgm
 2 over
1h. Treatment was continued until progressive disease (PD) or
toxicity occurred, according to the standard criteria (Therasse
et al, 2000) or the specific trial guidelines.
Clinical evaluation and response criteria
The response was assessed every 6 weeks with radiological
examination (computerised tomodensitometry or magnetic reso-
nance imaging). The RECIST (Response Evaluation Criteria in
Solid Tumors) criteria were adopted for evaluation, and classified
into partial response (PR), stable disease (SD) and PD. Patients
with SD or PD were defined as nonresponders (Therasse et al,
2000). Response to therapy was also evaluated retrospectively by
independent radiologists.
Molecular analyses
Primary tumour specimens were fixed in 10% buffered formalin
and embedded in paraffin, and data processing was accomplished
at the Institute of Pathology, Locarno, Switzerland. All formalin-
fixed paraffin-embedded tumour blocks were reviewed for quality
and tumour content, and a single representative tumour block
from each case, containing at least 70% of neoplastic cells, was
selected for immunohistochemical, cytogenetic and molecular
analyses. Genomic DNA was extracted using the QIAamp Mini kit
(Qiagen, Chatsworth, CA, USA) according to the manufacturer’s
instructions.
Epidermal growth factor receptor: IHC Epidermal growth factor
receptor protein expression was evaluated using the EGFR
PharmDX kit (Dako Cytomation, Glostrup, Denmark) on 3-mm
thick tissue sections without knowledge of clinical data or the
results of other analyses. The intensity of reaction was classified as
score 1þ,2þ or 3þ, on the basis of the percentage of positive
cells and the intensity of staining, according to the manufacturer’s
instructions (o5%, 5–50% and 450% of cells, respectively). As
controls, we used those included in the kit.
Microsatellite instability The status of microsatellite instability
(MSI) was assessed by the analysis of the microsatellite loci included
in the panel of Bethesda (BAT25, BAT26, D2S123, D5S346, D17S250),
as reported previously (Frattini et al, 2004). Microsatellite instability
was confirmed by the presence of an additional peak in tumour
sample in comparison with normal paired tissue.
Table 1 Patient’s characteristics and response by treatment
Patients Sex
Age
(years) Previous therapies Cetuximab line Regimen Best response
Duration of
response (weeks)
1 F 65 FOLFOX 2nd CPT11-b/r+cetuximab (CT) PR 8
2 M 67 FOLFOX; CPT11 3rd CPT11-b/r+cetuximab PD NA
3 M 60 FOLFOX; CAP; FOLFIRI 4th CPT11-b/r+cetuximab (CT) PD NA
4 M 82 CAPOX 2nd CPT11-b/r+cetuximab (CT) PD NA
5 M 78 CAP; FOLFOX; FOLFIRI 4th CPT11-b/r+cetuximab (CT) PD NA
6 F 63 CPT11 2nd CPT11-b/r+cetuximab (CT) PD NA
7 M 72 CPT11 2nd CPT11-b/r+cetuximab (CT) PD NA
8 F 59 FOLFIRI 2nd CPT11-b/r+cetuximab (CT) PR 48
9 M 69 FOLFIRI 2nd CPT11-b/r+cetuximab (CT) PR 16
10 M 59 FOLFOX; FOLFIRI 3rd CPT11-b/r+cetuximab PR 48
11 M 67 FOLFOX; CPT11 3rd CPT11-b/r+cetuximab (CT) PD NA
12 M 69 FOLFOX 2nd CPT11-b/r+cetuximab (CT) PD NA
13 M 79 CAPOX; CPT11 3rd CPT11-b/r+cetuximab PR 13
14 M 65 None 1st CAPOX+cetuximab (CT) PD NA
15 F 75 CAPOX; FOLFIRI 3rd CPT11-b/r+cetuximab PD NA
16 M 64 5FU; CAPOX; FOLFIRI 4th CPT11-b/r+cetuximab (CT) PR 12
17 M 72 FOLFOX; CAPIRI 3rd CPT11-b/r+cetuximab (CT) PR 28
18 F 72 5FU/LV; CPT11 3rd CPT11-b/r+cetuximab (CT) SD 8
19 M 66 CAPIRI; CPT11 3rd CPT11-b/r+cetuximab PD NA
20 F 63 None 1st CAPOX+cetuximab (CT) PR 8
21 F 84 CAP; CPT11 3rd CPT11-b/r+cetuximab PD NA
22 M 59 CAPOX/BV; FOLFIRI 3rd CPT11-b/r+cetuximab SD 1
23 M 78 FOLFOX; CPT11 3rd CPT11-b/r+cetuximab PD NA
24 F 29 FOLFOX; FOLFIRI 3rd CPT11-b/r+cetuximab (CT) SD 16
25 M 58 FOLFOX; CPT11 3rd CPT11-b/r+cetuximab PR 16
26 M 70 None 1st CAPOX+cetuximab (CT) PR 13
27 F 44 None 1st CAPOX+cetuximab (CT) PD NA
Abbreviations: BV, bevacizumab; CAP, capecitabine; CAPIRI, irinotecan and CAP; CAPOX, oxaliplatin and CAP; CPT11-b/r, irinotecan-based regimen; CT, clinical trial; F, female;
5FU, fluorouracil; FOLFIRI, irinotecan, 5FU and folinic acid; M, male; FOLFOX, oxaliplatin, 5FU and folinic acid; NA, not applicable; PD, progressive disease; PR, partial response;
SD, stable disease.
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tion Epidermal growth factor receptor gene status evaluation was
performed by fluorescent in situ hybridization (FISH) on 3-mm
thick tissue sections. Tissue sections were treated using Paraffin
Pretreatment kit II (Vysis, Downer’s Grove, IL, USA) according to
the manufacturer’s instructions. Dual-colour FISH assay was
performed using LSI EGFR/CEP7 probes (Vysis). The LSI EGFR
probe is labelled in SpectrumOrange and covers an approximately
300kb region that contains the entire EGFR gene at 7p12. The
CEP7 probe, labelled in SpectrumGreen, hybridises to the alpha
satellite DNA located at the centromere of chromosome 7 (7p11.1–
q11.1). Target sections and probe were co-denatured at 751C for
5min and allowed to hybridise overnight at 371C. Post-hybridisa-
tion stringency wash was carried out in water bath at 721C for
5min. After washing twice and drying at room temperature for
10min, slides were mounted with 406-diamidino-2-phenylindole
(DAPI II; Vysis). Fluorescent in situ hybridization signals were
evaluated with a Zeiss Axioscope equipped with single and triple
band pass filters. Image for documentation were captured using
AxioCam camera and processed using the AxioVision system.
Patients showing two chromosome 7 in the vast majority of cells
were classified as eusomic. Patients with an aberrant number of
chromosome 7, defined as more than 4 in at least 50% of cells, were
classified as markedly polysomic. Patients with a ratio more than 3
between EGFR gene and chromosome 7 centromere signals in at
least 10% of cells were classified as having EGFR gene amplification.
K-Ras mutational status: sequencing We searched for K-Ras
point mutations in codons 12 and 13, two hotspots that include
more than 95% of mutations in this gene, as already reported
(Frattini et al, 2004). All samples were subjected to automated
sequencing by ABI PRISM 3100 (Applied Biosystems, Foster City,
CA, USA) and analysed with Chromas software. Each sequence
reaction was performed at least twice, starting from independent
PCR reactions. In each case, the detected mutation was confirmed
in the sequence as sense and antisense strands.
PTEN expression: IHC PTEN protein expression status by IHC on
3-mm tissue sections was performed and evaluated according to the
literature (Frattini et al, 2005; Saal et al, 2005). The Anti-PTEN
Ab-2 (Neomarkers, Fremont, CA, USA) was applied at 1:50
dilution. PTEN protein expression was detected mainly at
cytoplasmic level, although occasional nuclear positivity was
present. We considered PTEN negative tumours those showing a
dramatical reduction or absence of immunostaining in at least 50%
of cells, as compared with the internal control. The evaluations
were performed without knowledge of clinical data or the results of
other analyses.
Statistical considerations
The objective tumour response was the end point of our
exploratory study. The two-tailed Fisher’s exact test was used to
calculate P-value for association between the gene alterations and
response to cetuximab. The level of significance was set at P¼0.05.
The OS time was calculated as the period from the first day of
cetuximab treatment until death from any cause, or the date of the
last follow-up.
RESULTS
A total of 27 patients were analysed, including nine women and
18 men, with a median age of 67 years (range, 29–84 years). Colon
and rectal cancers were diagnosed in 19 and eight patients,
respectively, and synchronous metastases were found in 19
patients (70%). Cetuximab was administered in combination with
chemotherapy as upfront therapy in four cases, as second line in
seven cases, as third line in 13 patients and as fourth line in three
cases. Ten patients (37%) achieved PR after cetuximab-based
therapy, and the median duration of response was 21 months
(range, 8–48 months). Characteristics and response by treatment
are summarised in Table 1.
Microsatellite instability
Using the Bethesda panel, none of tumours showed MSI (data not
shown).
Epidermal growth factor receptor: IHC and FISH
Table 2 summarises the immunohistochemical, cytogenetic and
molecular features. All patients had EGFR-positive tumours at
IHC, five cases (19%) were classified as score 1þ, nine cases
(33%) as score 2þ and 13 (48%) as score 3þ. By FISH, three
(11%) patients showed eusomy, 16 (59%) patients were highly
polysomic on chromosome 7 and eight (30%) patients showed
EGFR amplification (Figure 1). Five patients (Table 2) presented
rare cells with EGFR amplification associated with a large majority
(450%) of cells with marked polysomy, and consequently they
were classified as highly polysomic. We did not find any significant
correlation by comparing the EGFR protein expression (by IHC)
and its gene status (by FISH). In fact, those with eusomy showed
either score 1þ (66%) or score 3þ staining (33%). Polysomy
correlated with score 1þ in 6%, score 2þ in 44% and score 3þ
in 50%. Patients who had gene amplification were equally
distributed, with prevalence in favour of score 3þ (score 1þ,
2þ and 3þ: 25, 25 and 50%, respectively).
Table 2 Immunohistochemical, cytogenetic and molecular data
Patients EGFR: IHC EGFR: FISH K-Ras: status PTEN: IHC
1 1+ A WT Pos
2 2+ A 13GaC Neg
3 3+ P 12GcT Pos
4 1+ P WT Neg
5 3+ P 12GcT Pos
6 2+ P 12GaT Neg
7 2+ P WT Neg
8 3+ A WT Pos
9 3+ A WT Pos
10 2+ P* WT Pos
11 1+ E 13GaC Neg
12 3+ E 12GaT Pos
13 3+ A WT Pos
14 3+ P* WT Neg
15 2+ A 12tGT Neg
16 2+ P WT Pos
17 1+ A WT Pos
18 2+ P* 12GaT Pos
19 3+ P* WT Neg
20 3+ P 13GaC Pos
21 3+ P 12GaT Pos
22 1+ E WT Pos
23 3+ P WT Neg
24 3+ P WT Neg
25 3+ A WT Pos
26 2+ P* WT Pos
27 2+ P WT Neg
Total 5/27 (19%)
score 1+
8/27 (30%) A 17/27 (63%) WT 16/27¼59% Pos
9/27 (33%)
score 2+
16/27 (59%) P 10/27 (37%)
Mutated
11/27¼42% Neg
13/27 (48%)
score 3+
3/27 (11%) E
Abbreviations: A, EGFR gene amplification; P, chromosome 7 polysomy; P*, polysomy
with rare cells showing EGFR amplification; E, eusomy; WT, wild type; Pos, positive;
Neg, negative.
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Seventeen patients did not show K-Ras mutations. Point mutations
were found in 37% of cases, in seven patients on codon 12 and in
three patients on codon 13 (Table 2). Mutations on codon 12
predominantly involved the second base, with prevalence of the
GaT mutation (GGT-GaT, Gly-Asp, G12D), which was observed
in four cases. In one case, the mutation on codon 12 involved the
first base (GGT-tGT, Gly-Cys, G12C). No GtT alteration on
codon 12 was found, which represents one of the most frequent
mutations observed in sporadic CRC. The mutations found on
codon 13 corresponded to the transition G-A to the second base
of the codon (GGC-GaC, Gly-Asp, G13D).
PTEN: IHC
Normal PTEN expression was documented in 16 (59%) patients,
while loss of PTEN protein expression was found in 11 patients
(Figure 2).
Molecular markers and response to cetuximab
Eusomic patients did not respond to cetuximab-based therapy. An
objective response was observed in four out 16 (25%) patients with
polysomy, while six out eight (75%) patients with EGFR
amplification were considered as responders (Table 3). The
correlation of the EGFR gene status and response reached
statistical significance (Po0.05).
Only one out 10 (10%) patients with mutated K-Ras experienced
a response to cetuximab-based therapy, while nine out of 17 (53%)
patients with wild-type sequence had a benefit from therapy. The
correlation of the K-Ras status and response reached statistical
significance (Po0.05) (Table 3). The kind of mutation observed
did not influence the response.
As regards to PTEN, 10 of 16 (62.5%) patients with intact
protein expression had an objective response to cetuximab-based
therapy (Table 3). In contrast, none of the 11 patients with loss of
AB
C
Figure 1 Epidermal growth factor receptor gene status evaluated by FISH in metastatic colorectal cancers. (A) Patient showing eusomy of chromosome
7. (B) Patient with marked polysomy on chromosome 7. (C) Patient with EGFR gene amplification in at least 10% of tumoral cells.
A
B
Figure 2 PTEN protein expression by immunohistochemistry in
metastatic colorectal cancers. (A) Patient showing normal PTEN expression.
(B) Patient with absent PTEN expression.
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(Po0.001).
DISCUSSION
The Food and Drug Administration (FDA) approved cetuximab in
2004 for treatment of mCRC in combination with irinotecan, as
well as in monotherapy in patients intolerant to irinotecan.
However, only a minority of patients respond to cetuximab-based
therapy, and there are currently no molecular markers able to
identify patients who will benefit from this therapeutic approach.
A better understanding of molecular mechanisms that may predict
resistance or response to cetuximab is therefore urgently needed.
Similarly to previous reports (Cunningham et al, 2004; Saltz
et al, 2004), we observed no correlation between the intensity of
EGFR expression as detected by IHC and response to cetuximab-
based therapy. In the present cohort, eusomic patients who did not
respond to cetuximab were actually classified either score 1þ
(66%) or score 3þ (33%). These results are in agreement with
those from two small trials, showing that EGFR evaluation using
IHC is misleading in predicting response to the MoAb. Moreover,
in a retrospective series of 16 chemo-refractory patients not
expressing EGFR, cetuximab was shown to produce an RR of 25%
(Chung et al, 2005). In addition, two PR were seen in nine patients
with EGFR-negative tumours enrolled in a phase II study of single
agent cetuximab (Lenz et al, 2005). It has been shown that the
choice of fixative and storage time of tumour tissue, (Atkins et al,
2004) the choice of primary antibody and scoring system (Kersting
et al, 2006), and the lack of standardised criteria for evaluation
(Langner et al, 2004) all represent potential pitfalls and have a
substantial impact on determination of EGFR immunoreactivity. It
is therefore highly questionable whether mCRC patients should be
selected for cetuximab-based therapy only on EGFR reactivity by
IHC.
Our results indicate that both high polysomy on chromosome 7
and EGFR gene amplification appear to be a pre-requisite for
response to cetuximab (observed in 25 and 75% of cases,
respectively). Supporting this hypothesis, three eusomic patients
had no benefit from the MoAb. Our findings are consistent with
those reported (Moroni et al, 2005; Lievre et al, 2005). Of note, in
one of these, patients with trisomy were defined as polysomic and
benefited from the drug in 89% of cases (Moroni et al, 2005). In
our series, however, 12 cases with high polysomy on chromosome
7 and two cases with EGFR gene amplification did not benefit from
cetuximab. Consequently, the evaluation of the EGFR gene status
appears to be insufficient to predict response to the MoAb.
In the present cohort, the majority (90%) of patients with
mutated K-Ras did not benefit from cetuximab. Similar results
have been reported in two additional trials, whereas in another
study a not significant trend was observed. If we pool our data with
those of these three studies (Moroni et al, 2005; Lievre et al, 2006;
Di Fiore et al, 2007), the difference between K-Ras mutated and
K-Ras wild-type sequence patients as regards to cetuximab
treatment is highly significant, indicating that the assessment of
K-Ras mutations in mCRC plays a fundamental role in predicting
cetuximab efficacy. As regards to the type of K-Ras mutation, the
mostly observed alterations occurred on codon 12 (70%), against
30% on codon 13. These findings are consistent with previous
reports (Frattini et al, 2004). Interestingly, besides the expected
occurrence of GaT mutation, no alterations of GtT (the other most
frequently observed K-Ras mutation in sporadic CRC) (Frattini
et al, 2004) were found on codon 12. The present data reinforce,
therefore, the knowledge that the GtT mutation typically correlates
with an indolent clinical course, and seldom occurs in mCRC (Sarli
et al, 2004).
Other factors besides the EGFR gene status and K-Ras mutations
are likely to be involved in mechanisms of resistance to cetuximab.
The EGFR signal activation leads not only to downstream effects
on Ras-MAP kinase pathway, but also regulates the PTEN-PI3K-
Akt cascade. The loss of expression of PTEN protein has been
observed in 30% of sporadic CRC (Thomas and Grandis, 2004). No
data on PTEN protein expression and correlation with response
to cetuximab in mCRC have been reported yet. We demonstrate
that loss of PTEN protein expression may be a useful marker in
predicting response to cetuximab. In fact, none of the 11 patients
with loss of PTEN expression did benefit from the treatment with
MoAb, while a response was observed in 10 out of 16 patients
with intact PTEN expression. The six patients with intact PTEN
expression who did not benefit from cetuximab had K-Ras
mutation in four cases, eusomy in one case and both in one case:
all these factors have been shown to predict resistance to
cetuximab.
The effect of PTEN expression on cetuximab response is similar
to the one observed in trastuzumab-treated breast cancer patients
(Pandolfi, 2004), supporting the concept that PTEN expression
plays a fundamental role in predicting the response to drugs
against HER family members.
The population of the present study is comparable with those
of previous related studies in terms of included patients, and it is
homogeneous since it encompasses unselected patients native
from an isolated geographic area, all evaluated and treated in one
institution. None of the patients were found to exhibit MSI, which
suggests that tumour development in our patients followed the
same pathway (Fearon and Vogelstein, 1990). Actually, the rate of
PR (37%) is surprisingly high when compared with published data
of pivotal trials including cetuximab (Cunningham et al, 2004).
On the other hand, our cohort is characterised by high frequency
of polysomy and EGFR gene amplification. We can therefore
mCRC
EGFR by FISH on primary tumour
Eusomy
Chromosome 7
marked polysomy
No cetuximab
EGFR gene
amplification
Cetuximab
PTEN+
K-Ras wt
PTEN–
K-Ras wt
PTEN +
K-Ras mut
PTEN–
K-Ras mut
Resistance Response
Figure 3 Algorithm in predicting response to cetuximab according to
the EGFR and K-Ras status, and PTEN protein expression.
Table 3 EGFR and K-Ras gene status, PTEN protein expression:
correlation with clinical response to cetuximab
EGFR (FISH) K-Ras PTEN
E P A WT Mut Pos Neg
Clinical response to PR 0 4 6 9 1 10 0
Cetuximab NR 3 12 2 8 9 6 11
Fisher exact test Po0.05 Po0.05 Po0.001
Abbreviations: PR, partial response; NR, nonresponder; E, eusomy; P, chromosome 7
polysomy; A, EGFR gene amplification; WT, wild type; Mut, mutated; Pos, positive;
Neg, negative.
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to frequent cell division deregulation (as deductible by the
observed high rate of polysomy) and to EGFR gene amplification.
Although the clinical course might be more aggressive, this
particular constellation makes perhaps a targeted approach more
effective than expected.
The possibility that the present findings are related to the
response to the previous chemotherapy regimen rather than
cetuximab sensitivity or resistance may raise questions on the
validity of our as well as previous results. This hypothesis,
however, is unlikely since all patients included in this study were
refractory to previous chemotherapeutic treatment, and drugs,
such as fluoropirimidines, oxaliplatin and irinotecan, act against
thymidylate synthase and topoisomerase I and not against the
EGFR signalling pathway.
Overall, our findings allow to propose an algorithm in order to
possibly select patient for cetuximab therapy (Figure 3). Those
presenting with eusomy on chromosome 7 are more likely to be
refractory to the MoAb, while patients with high polysomy or
EGFR gene amplification should be considered for cetuximab
therapy. A benefit from the MoAb may be expected in patients
presenting with wild-type K-Ras and intact PTEN expression. Only
one patient escaped to this algorithm, in that he responded to
cetuximab in presence of K-Ras mutation. A possible explanation
could be that in our series all molecular analysis have been
performed on primary CRC, and the gene profile on primary
tumour and metastasis might differ, as previously reported
(Scartozzi et al, 2004).
In conclusion, our results indicate that different downstream
proteins of the EGFR cascade have a deep effect on response to
cetuximab. In particular, this is the first report on the predictive
role of the expression of PTEN protein in mCRC. These data,
which need to be validated in large prospective clinical trials,
might represent a valid platform for oncologists in selecting
patients for cetuximab-based therapy, with evident clinical and
economical consequences.
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